Cited by 900Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsMicrotubule and mitosis dynamics

The many faces of tau

Open access
Morris, Meaghan, Maeda, Sumihiro, Vossel, Keith, Mucke, Lennart·2011·Neuron

Abstract

While the microtubule-binding capacity of the protein tau has been known for many years, new functions of tau in signaling and cytoskeletal organization have recently emerged. In this review, we highlight these functions and the potential roles of tau in neurodegenerative disease. We also discuss the therapeutic potential of drugs targeting various aspects of tau biology.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neuron.2011.04.009

Cites

200 of 200 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In mice, a 50% reduction of endogenous tau markedly reduces amyloid β- and ApoE4 fragment-induced neuronal and cognitive impairments in vivo.

    “markedly reduces amyloid 𝛃 and ApoE4 fragment-induced neuronal and cognitive impairments in vivo (34)”

    From An Unbiased Approach to Identifying Tau Kinases That Phosphorylate Tau at Sites Associated with Alzheimer Disease (2013) · cites this paper as [34]

    The section “Reduction of overall tau levels” says that partial tau reduction in mice markedly diminishes Aβ- and ApoE-induced neuronal and cognitive impairments in vivo. The copy does not specify a 50% reduction for this result or identify the ApoE-induced impairments as caused by ApoE4 fragments; “Tau Functions Enabling Pathogenesis” discusses apoE4 more generally. Page numbers were not available in the indexed passages. (LLM, conf=0.85)

    Experimental — accuracy not yet measured
  • Reductions in tau levels prevent amyloid β from causing neuronal deficits in cell culture and in transgenic mice expressing human amyloid precursor protein.

    “Reductions in tau levels have also been shown to prevent amyloid 𝛃 from causing neuronal deficits in cell culture and in transgenic mice expressing human amyloid precursor protein (34).”
  • In mice, a 50% reduction of endogenous tau is well tolerated.

    “in mice a 50% reduction of endogenous tau is well tolerated”
  • The interaction of tau with microtubules in neurons is well documented and more recent studies have proposed that tau also binds to actin.

    “The interaction of tau with microtubules in neurons is well documented and more recent studies have proposed that tau also binds to actin34.”

    From Tau co-organizes dynamic microtubule and actin networks (2015) · cites this paper as [34]

  • Tauopathies are neurodegenerative diseases characterized by pathological accumulation of hyper-phosphorylated tau in paired helical filaments or neurofibrillary tangles within neurons and glia of affected brain regions, leading to cell death.

    “Tauopathies are neurodegenerative diseases characterized by aberrant forms of tau protein accumulation leading to neuronal death in focal brain areas.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Morris, M., Maeda, S., Vossel, K., & Mucke, L.
Affiliations
Gladstone Institutes (US)
Corresponding author
Mucke, Lennart
Venue
Neuron
Publisher
Elsevier BV
Published
2011-05
Volume
70
Issue
3
Pages
410-426
ISSN
0896-6273 (ISSN-L)
OpenAlex
W2125985978
Cited by
899
References
196
Citations by year
2026: 29 · 2025: 33 · 2024: 36 · 2023: 52 · 2022: 59 · 2021: 65 · 2020: 59 · 2019: 59 · 2018: 72 · 2017: 65 · 2016: 67 · 2015: 70 · 2014: 67 · 2013: 80 · 2012: 59
FWCI
7.63
Type
journal article
Language
en
Open access
Locations
  • Neuron (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (AG011385, NS041787)
  • Tau Consortium
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
Keywords
tau protein, microtubule binding, cytoskeletal organization, signaling, neurodegenerative diseases, tauopathy
MeSH terms
Animals, Humans, Microtubules, Models, Biological, Signal Transduction, tau Proteins, Neurodegenerative Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review